West Oak Capital Boosted By $9.67 Million Its Lilly Eli & Company (LLY) Position; Delek Logistics Partners LP (DKL)’s Sentiment Is 0.55

Eli Lilly and Company (NYSE:LLY) Logo

Delek Logistics Partners LP (DKL) investors sentiment decreased to 0.55 in 2018 Q1. It’s down -0.31, from 0.86 in 2017Q4. The ratio turned negative, as 12 active investment managers increased or opened new stock positions, while 22 sold and trimmed stock positions in Delek Logistics Partners LP. The active investment managers in our database now possess: 5.70 million shares, down from 5.91 million shares in 2017Q4. Also, the number of active investment managers holding Delek Logistics Partners LP in top ten stock positions was flat from 0 to 0 for the same number . Sold All: 7 Reduced: 15 Increased: 8 New Position: 4.

West Oak Capital Llc increased Lilly Eli & Company (LLY) stake by 2.02% reported in 2018Q1 SEC filing. West Oak Capital Llc acquired 125 shares as Lilly Eli & Company (LLY)’s stock rose 3.23%. The West Oak Capital Llc holds 6,325 shares with $489.37 million value, up from 6,200 last quarter. Lilly Eli & Company now has $88.62 billion valuation. The stock increased 0.82% or $0.71 during the last trading session, reaching $86.82. About 3.04 million shares traded. Eli Lilly and Company (NYSE:LLY) has risen 5.65% since June 20, 2017 and is uptrending. It has underperformed by 6.92% the S&P500. Some Historical LLY News: ; 23/04/2018 – FDA PANEL VOTES 9-6 TO BACK SAFETY DATA ON BARICITINIB 2MG; 18/05/2018 – FDA – MERCK, GENENTECH HAVE STOPPED ENROLLING PATIENTS WHOSE TUMORS HAVE PD-L1 LOW STATUS TO KEYTRUDA/TECENTRIQ MONOTHERAPY ARMS PER DMCS’ RECOMMENDATIONS; 17/05/2018 – SYNDAX: ENTINOSTAT/KEYTRUDA TRIAL SUGGESTS `ENHANCED BENEFIT`; 06/03/2018 – Bristol-Myers: FDA Approves Supplemental Biologics License Application Updating Opdivo Dosing Schedul; 14/05/2018 – Eli Lilly to Pay $110 Million Upfront to AurKa Shareholders; 16/05/2018 – Merck:Evidence Continues to Support the Role of KEYTRUDA as a Foundational Treatment for Many Types of Cancer; 06/04/2018 – Lilly set to collect initial Elanco bids – sources [19:23 BST06 Apr 2018] [Proprietary] []; 20/04/2018 – LILLY REPORTS ADDED TOP-LINE FROM CYRAMZA PHASE 3 RANGE STUDY; 24/04/2018 – ELI LILLY AND CO – QTRLY CYMBALTA SALES $169.6 MLN VS $174.6 MLN REPORTED LAST YEAR; 27/03/2018 – Bristol-Myers: FDA Accepts Application for Opdivo Plus Yervoy for Previously Treated Patients With MSI-H or dMMR Metastatic Colorectal Cancer for Priority Review

West Oak Capital Llc decreased Ingersoll Rand Co Cl A stake by 150 shares to 4,498 valued at $384.62M in 2018Q1. It also reduced Danaher Corp Del (NYSE:DHR) stake by 141 shares and now owns 22,128 shares. Disney Walt Co (NYSE:DIS) was reduced too.

Among 23 analysts covering Eli Lilly and Company (NYSE:LLY), 14 have Buy rating, 1 Sell and 8 Hold. Therefore 61% are positive. Eli Lilly and Company has $125 highest and $64 lowest target. $93.76’s average target is 7.99% above currents $86.82 stock price. Eli Lilly and Company had 105 analyst reports since July 23, 2015 according to SRatingsIntel. As per Tuesday, January 16, the company rating was downgraded by Goldman Sachs. The firm has “Buy” rating given on Monday, July 17 by Jefferies. Goldman Sachs upgraded the stock to “Buy” rating in Tuesday, September 27 report. As per Friday, September 15, the company rating was maintained by Jefferies. On Monday, July 17 the stock rating was maintained by Deutsche Bank with “Buy”. The stock of Eli Lilly and Company (NYSE:LLY) has “Outperform” rating given on Monday, December 28 by Leerink Swann. The rating was upgraded by Barclays Capital on Tuesday, December 1 to “Overweight”. The firm has “Buy” rating given on Tuesday, May 30 by Jefferies. The firm has “Neutral” rating given on Thursday, February 1 by Bank of America. The rating was maintained by Morgan Stanley with “Equal-Weight” on Tuesday, November 21.

More notable recent Eli Lilly and Company (NYSE:LLY) news were published by: Seekingalpha.com which released: “Alzheimer’s Disease: A History Of Drug Failures” on June 19, 2018, also Streetinsider.com with their article: “Lilly (LLY) and AstraZeneca (AZN) Halt Phase 3 Trials of Lanabecestat for Alzheimer’s Disease Due to Futility” published on June 12, 2018, Seekingalpha.com published: “Avoiding The ‘Black Hole’ Of Disease Development” on June 15, 2018. More interesting news about Eli Lilly and Company (NYSE:LLY) were released by: Schaeffersresearch.com and their article: “Analyst: Eli Lilly Assets Are ‘Underappreciated'” published on June 08, 2018 as well as Seekingalpha.com‘s news article titled: “There Is A Lot Going On Underneath The Market – Cramer’s Mad Money (6/11/18)” with publication date: June 12, 2018.

Since February 1, 2018, it had 1 insider buy, and 19 insider sales for $92.69 million activity. 180,000 Eli Lilly and Company (NYSE:LLY) shares with value of $15.60M were sold by LILLY ENDOWMENT INC. $1.81 million worth of Eli Lilly and Company (NYSE:LLY) shares were sold by Mahony Susan. Zakrowski Donald A sold $67,934 worth of Eli Lilly and Company (NYSE:LLY) on Wednesday, February 21. Another trade for 25,000 shares valued at $2.13M was made by Conterno Enrique A on Thursday, May 31. Smiley Joshua L also sold $237,600 worth of Eli Lilly and Company (NYSE:LLY) on Friday, March 16. Simmons Jeffrey N also sold $708,620 worth of Eli Lilly and Company (NYSE:LLY) on Tuesday, May 1. On Tuesday, May 29 Shaw Christi sold $691,775 worth of Eli Lilly and Company (NYSE:LLY) or 8,426 shares.

Investors sentiment decreased to 0.78 in Q1 2018. Its down 0.32, from 1.1 in 2017Q4. It is negative, as 76 investors sold LLY shares while 427 reduced holdings. 82 funds opened positions while 308 raised stakes. 810.94 million shares or 1.95% less from 827.08 million shares in 2017Q4 were reported. Moors & Cabot has invested 0.31% in Eli Lilly and Company (NYSE:LLY). Sei Invests Company holds 0.19% in Eli Lilly and Company (NYSE:LLY) or 650,913 shares. Connors Investor Svcs reported 0.7% of its portfolio in Eli Lilly and Company (NYSE:LLY). Westfield Cap Management Communications Lp invested in 0.07% or 109,170 shares. 17,278 were accumulated by Sigma Planning. Destination Wealth Management holds 0% or 103 shares in its portfolio. Oak Ridge Invs Lc accumulated 0.58% or 134,675 shares. Moreover, Intl Incorporated Ca has 0.19% invested in Eli Lilly and Company (NYSE:LLY). Sio Capital Management Ltd Liability reported 3.83% stake. Hilltop Inc invested 0.05% in Eli Lilly and Company (NYSE:LLY). Liberty Mutual Group Asset Mngmt Inc reported 38,615 shares stake. Boston Family Office Ltd Com owns 9,915 shares or 0.09% of their US portfolio. Mcgowan Asset Mgmt owns 0.28% invested in Eli Lilly and Company (NYSE:LLY) for 21,349 shares. Axa holds 0.35% of its portfolio in Eli Lilly and Company (NYSE:LLY) for 1.12M shares. Old Mutual Customised Solutions (Proprietary) Limited has invested 0.15% in Eli Lilly and Company (NYSE:LLY).

The stock increased 0.36% or $0.1 during the last trading session, reaching $27.5. About 31,614 shares traded. Delek Logistics Partners, LP (DKL) has declined 4.86% since June 20, 2017 and is downtrending. It has underperformed by 17.43% the S&P500. Some Historical DKL News: ; 14/05/2018 – Delek US Holdings to Participate in the Citi 2018 Global Energy & Utilities Conference; 04/04/2018 – DNO Pays GBP70.4 Mln for Delek Group’s Stake in Faroe Petroleum; 25/05/2018 – Delek US and Delek Logistics Announce Regina Jones has Joined the Companies as EVP, General Counsel and Secretary; 14/03/2018 – Delek Logistics Partners, LP 2017 K-1 Tax Packages Available on Website; 07/03/2018 – DELEK, NOBLE SAY IN TALKS TO BUY RIGHTS TO USE EMG PIPELINE FOR NATURAL GAS SUPPLY TO EGYPT; 07/03/2018 – Delek Group Closes Above 50-Day Moving Average: Technicals; 07/05/2018 – DELEK BOOSTS QTR DIV TO 25C/SHR FROM 20C, EST. 20C; 04/04/2018 – DNO ASA DNO.OL – DNO ASA, NORWEGIAN OIL AND GAS OPERATOR, TODAY ANNOUNCED THAT IT HAS AGREED TO ACQUIRE 15.37 PERCENT OF SHARE CAPITAL OF FAROE PETROLEUM PLC FROM DELEK GROUP LTD; 07/03/2018 DELEK DRILLING, NOBLE BEGIN TALKS WITH EMG ON USING PIPELINE; 21/03/2018 – Aphrodite Partners in Talks to Sell 6 Bcm/Yr to Shell: Delek

Delek Logistics Partners, LP owns and operates logistics and marketing assets for crude oil, and intermediate and refined products in the United States. The company has market cap of $684.25 million. It operates in two divisions, Pipelines and Transportation, and Wholesale Marketing and Terminalling. It has a 12.22 P/E ratio. The Pipelines and Transportation segment consists of assets, including pipelines and trucks, and ancillary assets that provide crude oil gathering and crude oil, intermediate and finished products transportation, and storage services primarily in support of the Tyler and El Dorado refineries, as well as offers crude oil and other products transportation services to third parties.

Since January 1, 0001, it had 1 insider purchase, and 2 selling transactions for $101,888 activity.

More recent Delek Logistics Partners, LP (NYSE:DKL) news were published by: Seekingalpha.com which released: “90 Champions, Contenders And Challengers Are Wall Street Dividend Stars For June” on June 12, 2018. Also Globenewswire.com published the news titled: “Report: Exploring Fundamental Drivers Behind Canadian Solar, Halcon Resources, Enstar Group, Delek Logistics …” on June 01, 2018. Globenewswire.com‘s news article titled: “Delek US and Delek Logistics Announce Regina Jones has Joined the Companies as EVP, General Counsel and …” with publication date: May 25, 2018 was also an interesting one.

Hite Hedge Asset Management Llc holds 2.11% of its portfolio in Delek Logistics Partners, LP for 341,292 shares. Advisory Research Inc owns 1.56 million shares or 0.79% of their US portfolio. Moreover, Arrow Investment Advisors Llc has 0.18% invested in the company for 21,604 shares. The New York-based Global X Management Co Llc has invested 0.15% in the stock. Parkside Financial Bank & Trust, a Missouri-based fund reported 9,710 shares.

Analysts await Delek Logistics Partners, LP (NYSE:DKL) to report earnings on August, 1. They expect $0.78 earnings per share, up 32.20% or $0.19 from last year’s $0.59 per share. DKL’s profit will be $19.41M for 8.81 P/E if the $0.78 EPS becomes a reality. After $0.59 actual earnings per share reported by Delek Logistics Partners, LP for the previous quarter, Wall Street now forecasts 32.20% EPS growth.

Delek Logistics Partners, LP (NYSE:DKL) Institutional Positions Chart